A Phase III clinical trial in China has found that stroke patients treated with loberamisal, a novel neuroprotective medication, had significantly better recovery compared to those who received a placebo. The study was presented as a late-breaking science presentation at the American Stroke Association’s International Stroke Conference 2026, held from February 4 to 6 in New Orleans.
Loberamisal is a small-molecule, dual-acting neuroprotective agent designed to protect brain cells within the first two days after a stroke. According to study author Shuya Li, M.D., director of the Clinical Trial Center at Beijing Tiantan Hospital, previous trials for neuroprotective agents have largely been unsuccessful, but loberamisal showed effectiveness in rodent studies. This trial aimed to test its efficacy in humans.
The study involved 998 adults aged 18 to 80 from 32 centers in China, all with moderate to severe ischemic stroke caused by a blocked vessel. Participants received either daily intravenous infusions of 40 mg loberamisal or a placebo for 10 days, starting within 48 hours of symptom onset. Only about 17% received standard clot-busting medication, limiting the assessment of combined effects. Patients who underwent mechanical thrombectomy were excluded.
At 90 days, 69% of those treated with loberamisal achieved excellent functional recovery (little to no disability) compared to 56% in the placebo group. The treatment was deemed safe, with no increased risk of serious side effects or death. The results are considered preliminary until published in a peer-reviewed journal.
The American Stroke Association’s new 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke notes renewed interest in neuroprotection, but current knowledge gaps remain. Li emphasized the need for further research in larger, more diverse populations to confirm findings and understand how loberamisal works at a biomarker level.
Study limitations include its conduct solely in China, which may affect generalizability, and the exclusion of patients with more severe strokes or those who had vascular surgery. No blood or imaging biomarkers were assessed. Despite these limitations, the results offer hope for a new treatment avenue for stroke, which remains a leading cause of death and disability worldwide. For more information on stroke resources, visit www.stroke.org. The American Heart Association’s 2026 Heart Disease and Stroke Statistics notes that stroke is now the #4 leading cause of death in the U.S., underscoring the urgent need for effective therapies.
